 Half-Life
"Half-Life" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity.
| Descriptor ID |
D006207
|
| MeSH Number(s) |
G01.910.405
|
| Concept/Terms |
Half-Life- Half-Life
- Half Life
- Half-Lifes
- Halflife
- Halflifes
|
Below are MeSH descriptors whose meaning is more general than "Half-Life".
Below are MeSH descriptors whose meaning is more specific than "Half-Life".
This graph shows the total number of publications written about "Half-Life" by people in this website by year, and whether "Half-Life" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 3 | 3 | | 1997 | 0 | 6 | 6 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 2 | 2 | | 2000 | 0 | 3 | 3 | | 2001 | 0 | 2 | 2 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 5 | 5 | | 2004 | 0 | 4 | 4 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 3 | 3 | | 2007 | 0 | 4 | 4 | | 2008 | 0 | 4 | 4 | | 2009 | 0 | 3 | 3 | | 2010 | 0 | 3 | 3 | | 2011 | 0 | 4 | 4 | | 2012 | 0 | 6 | 6 | | 2013 | 0 | 5 | 5 | | 2014 | 0 | 2 | 2 | | 2015 | 0 | 2 | 2 | | 2016 | 0 | 1 | 1 | | 2017 | 0 | 7 | 7 | | 2018 | 0 | 4 | 4 | | 2019 | 0 | 4 | 4 | | 2020 | 0 | 1 | 1 | | 2021 | 0 | 5 | 5 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Half-Life" by people in Profiles.
-
Adam E, Scollay M, Howard B, Taormina J, Hartmann P, Knych H. Detection of levamisole and its metabolites in horses after oral levamisole administration over seven days. J Am Vet Med Assoc. 2024 Dec 01; 262(12):1632-1638.
-
Rodrigues DC, Mufteev M, Yuki KE, Narula A, Wei W, Piekna A, Liu J, Pasceri P, Rissland OS, Wilson MD, Ellis J. Buffering of transcription rate by mRNA half-life is a conserved feature of Rett syndrome models. Nat Commun. 2023 04 05; 14(1):1896.
-
Manco-Johnson MJ, Warren BB. Long-term prophylaxis: what are our options and how to define success? Hematology Am Soc Hematol Educ Program. 2022 12 09; 2022(1):579-585.
-
McFarland EJ, Cunningham CK, Muresan P, Capparelli EV, Perlowski C, Morgan P, Smith B, Hazra R, Purdue L, Harding PA, Theron G, Mujuru H, Agwu A, Purswani M, Rathore MH, Flach B, Taylor A, Lin BC, McDermott AB, Mascola JR, Graham BS. Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants. J Infect Dis. 2021 12 01; 224(11):1916-1924.
-
Ahmed SK, Haese NN, Cowan JT, Pathak V, Moukha-Chafiq O, Smith VJ, Rodzinak KJ, Ahmad F, Zhang S, Bonin KM, Streblow AD, Streblow CE, Kreklywich CN, Morrison C, Sarkar S, Moorman N, Sander W, Allen R, DeFilippis V, Tekwani BL, Wu M, Hirsch AJ, Smith JL, Tower NA, Rasmussen L, Bostwick R, Maddry JA, Ananthan S, Gerdes JM, Augelli-Szafran CE, Suto MJ, Morrison TE, Heise MT, Streblow DN, Pathak AK. Targeting Chikungunya Virus Replication by Benzoannulene Inhibitors. J Med Chem. 2021 04 22; 64(8):4762-4786.
-
Yang B, Gelfanov VM, Perez-Tilve D, DuBois B, Rohlfs R, Levy J, Douros JD, Finan B, Mayer JP, DiMarchi RD. Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists. J Med Chem. 2021 04 22; 64(8):4697-4708.
-
Mann DM, Stafford KA, Poon MC, Matino D, Stafford DW. The Function of extravascular coagulation factor IX in haemostasis. Haemophilia. 2021 May; 27(3):332-339.
-
Manco-Johnson MJ, Warren BB, Buckner TW, Funk SM, Wang M. Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate). Haemophilia. 2021 Feb; 27 Suppl 3:87-95.
-
Liu XF, Wei J, Zhou Q, Molitoris BA, Sandoval R, Kobayashi H, Okada R, Nagaya T, Karim B, Butcher D, Pastan I. Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine. Proc Natl Acad Sci U S A. 2020 03 17; 117(11):6086-6091.
-
Yeom J, Guimaraes PPG, Ahn HM, Jung BK, Hu Q, McHugh K, Mitchell MJ, Yun CO, Langer R, Jaklenec A. Chiral Supraparticles for Controllable Nanomedicine. Adv Mater. 2020 Jan; 32(1):e1903878.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|